Shares of Summit Therapeutics (NASDAQ:SMMT) ended five straight sessions of gains on Friday as the stock lost ~35%, triggering a trading halt, a day after the FDA approved its partner Akeso’s (OTCPK:AKESF) first internally developed medicine.
Over 11.7M shares of